ClinicalTrials.gg
CompletedNCT00696137Updated Sep 24, 2019Results posted

Long-term Extension Study of BEMA™ Fentanyl

A Phase 3 interventional study of BEMA Fentanyl in Respiratory Depression, sponsored by BioDelivery Sciences International. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.

Read the detailed description

This was an open label, long-term, extension study designed to provide continued access to EMA Fentanyl to those patients with breakthrough cancer pain who were treated for at least 2 weeks in FEN-202, the long term safety study used for worldwide registration. Patients were followed in an outpatient setting. Use of BEMA Fentanyl and occurrence of serious adverse events (SAEs) were monitored. Throughout the study, all patients continued their background opioid regimen and were permitted to use their rescue medication if adequate pain relief was not realized within 30 minutes following application of BEMA Fentanyl.

02

Conditions studied

  • Respiratory Depression

Keywords

  • Chronic Pain
  • Ventilatory Response to Hypercapnia (VRH)
03

In context

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

This study's enrollment of 5 is below the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

BioDelivery Sciences International is the lead sponsor of 21 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. previously qualified for and participated in study FEN-202 for at least 2 weeks,
  2. wish to continue using BEMA Fentanyl for treatment of breakthrough pain episodes, and
  3. provide signed at screening prior to any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. they have developed a new medical condition after initial enrollment in FEN-202 which, in the opinion of the investigator, would preclude safe and appropriate use of BEMA Fentanyl or participation in this study, or
  2. there is evidence of improper use of the study drug.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    BEMA Fentanyl

    BEMA Fentanyl

    Drug: BEMA Fentanyl

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported.

    Efficacy was not measured in this study as the intention was to evaluate long term safety in this population. The number of deaths in the long term follow-up will be reported.

    Time frame: 3 years

07

Results

Posted Dec 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneBEMA Fentanyl
Started5
Completed3
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryEfficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported.

Efficacy was not measured in this study as the intention was to evaluate long term safety in this population. The number of deaths in the long term follow-up will be reported.

Time frame:
3 years
Reported as:
Count of participants · Participants
Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported.
ParticipantsBEMA Fentanyl
Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported.0

Adverse events

Collected over 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BEMA Fentanyl———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BEMA Fentanyl
<=18 years0
Between 18 and 65 years3
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)BEMA Fentanyl
Female3
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BEMA Fentanyl
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported0
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2018, 9 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2008
First posted
Jun 12, 2008
Start
Jun 2008
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Dec 19, 2018
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00696137
Lead sponsor
BioDelivery Sciences International
Responsible party
Sponsor
First posted
Jun 12, 2008
Start date
Jun 2008
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Dec 19, 2018
Last update
Sep 24, 2019

Study contacts

David Blum, MD
study chair · BioDelivery Sciences International

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl Buccal Soluble Film

Start the discussion